The interest in the identification of activators of HER2 was promoted by the finding that this membrane protein was overexpressed in a subset of patients with breast cancer, and such overexpression correlated with metastatic dissemination of the disease and poor patient outcome (Slamon et al., 1987). This evidence concerns the gene ERBB2 and breast carcinoma.